4 Healthcare Stock Stories for Investor Well-Being (ZIOP, KERX, STEM, CLSN)

Los Angelas, CA -- (SBWIRE) -- 02/12/2013 -- ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) shares increased 13%; announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS. According to the protocol and statistical plan, reaching the target number of PFS events leads to completion of the blinded data collection process and then formal efficacy analysis by the IDMC (Independent Data Monitoring Committee). The Company will announce topline results from this trial during the last week of March 2013.

Can ZIOP Extend Rally? Find Out Here

Keryx Pharma (NASDAQ:KERX) announced that Perifosine failed its Phase III trial for the treatment of colon cancer. Keryx licensed Perifosine from Aeterna, and after the failure, returned the drug back to Aeterna. Since then, both companies have gone in polar opposite directions as Keryx recently announced positive data for its Phase III drug Zerenex, designed to treat chronic kidney disease. Keryx recently hit a 52 week high of $9.98 on January 31st. On a side note, investors might want to take a hard look at Keryx moving forward. Keryx could end up being a great success story in the making for some time to come.

How Should Investors React To KERX Now? Find Out Here

StemCells, Inc. (NASDAQ:STEM) gained 25% higher; announced that the twelve-month data from the first patient cohort in the Company's Phase I/II clinical trial of its proprietary HuCNS-SC product candidate (purified human neural stem cells) for chronic spinal cord injury continued to demonstrate a favorable safety profile, and showed that the considerable gains in sensory function observed in two of the three patients at the six-month assessment have persisted. The third patient remains stable.

Can STEM Move Up Further? If Yes, How far It can Go? Find Out Here

Celsion Corporation (NASDAQ:CLSN) declined -7.08%, to $1.43, in the mid-day, with the overall traded volume of 5.00 million shares. Its fifty two week range was $1.13-$9.44. The total market capitalization remained $50.38 million. Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer.

How Should Investors Trade CLSN After The Recent Volatile Moves? Find Out Here

DISCLAIMER:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com